Posted: Tuesday, June 14, 2022
For patients with highly refractory and/or heavily pretreated diffuse large B-cell lymphoma (DLBCL), treatment with the novel T-cell–engaging bispecific antibody glofitamab may improve overall survival, according to a study presented at the European Hematology Association (EHA) 2022 Hybrid Congress (Abstract S220). Fixed-duration treatment with this novel therapy led to “durable” complete remissions in this patient population along with a “favorable” safety profile, explained Michael Dickinson, MBBS, of the University of Melbourne, Australia, and colleagues.
A total of 107 patients with DLBCL who had received at least two prior therapies were recruited for the study. Prior therapies included an anthracycline and anti-CD20 antibody. All patients were administered one dose of intravenous (IV) obinutuzumab 7 days before the first dose of glofitamab. Patients were given 12 cycles of a 21-day treatment regimen, which included a step-up dose of IV glofitamab on days 1 and 8 of the first cycle and a target dose of 30 mg on day 1 of cycles 2 through 12.
The study findings revealed a 50% and 35.2% overall response and complete response rate at a median follow-up of 9 months, respectively. In addition, a projected 12-month overall survival rate was 48%, and 92% of the complete responders survived. Furthermore, 68% of patients experienced symptoms of cytokine-release syndrome, particularly with initial doses.
In terms of safety, symptoms reported were primarily grade 1 (51%) or 2 (12%). Moreover, 3% of patients experienced glofitamab-related adverse events severe enough to require discontinuation of treatment.
Disclosure: For full disclosures of the study authors, visit library.ehaweb.org.